Clinical Trials Browser

Phase 1/2 × Glioblastoma × aldesleukin × Clear all

NCT01454596 2019-08-21

CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII

Phase 1/2 Completed

18 enrolled 25 charts

Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma